Navigation Links
Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
Date:4/17/2008

SEATTLE, April 17 /PRNewswire/ -- The state's Life Sciences Discovery fund has awarded $2.2 million to establish a formal phase 1 clinical-trials program to test new therapies for solid tumors at Fred Hutchinson Cancer Research Center. Announced this evening, the grant is among the first funded by Washington's $350 million tobacco-lawsuit-settlement bonus.

Developing novel therapies targeted to treat solid tumors, in collaboration with local biotechnology and pharmaceutical firms, is the goal of the Hutchinson Center/University of Washington Cancer Consortium. Phase 1 trials are by definition the first testing of cancer therapies in humans. The purpose is to determine whether and how a drug works.

Traditionally, phase 1 studies have been primarily concerned with drug safety. However, with the increased knowledge of the molecular pathways involved in cancer development, an ever-increasing proportion of drugs initially tested in humans prove to be effective, even in the first patients treated.

"Phase 1 trials are critically important, require a high level of unique competencies and, if done correctly, can substantially speed the development of new therapies," said Martin (Mac) Cheever, M.D., director of solid-tumor research at the Hutchinson Center. "This is an outcome that can benefit the state's patients, industry and health care enterprises."

Initially, the program will use the funding to develop a highly efficient infrastructure for implementing early phase -- primarily industry sponsored -- cancer clinical trials, and to provide exploratory funds that will allow Consortium researchers to apply their expertise in cancer imaging and biomarkers to cancer drug development.

The program will be led by John Thompson, M.D., as director of the Consortium phase 1 program. Thompson will be responsible for scientific direction and facilitating new industry and other trial sponsorships.

"Standard therapy for cancer is clearly inadequate," Cheever said. "The best hope is the development of new targeted therapies. Thanks to ever-advancing technologies and expanding basic knowledge of cancer biology -- areas of exceptional strength in the consortium -- the opportunities for developing new therapies targeted to cancer cells have never been greater."

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.

About the Life Sciences Discovery Fund

The Life Sciences Discovery Fund, a Washington State agency established in May 2005, makes grant investments in innovative life sciences research to benefit Washington and its citizens. For more information on the Life Sciences Discovery Fund, visit: http://www.lsdfa.org.

CONTACT

Dean Forbes

206-605-0311

dforbes@fhcrc.org


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
2. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
7. Cardiac Science to Present at the UBS Global Life Sciences Conference
8. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
9. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. Clarient to Present at the UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for ... and Congress to protect parental rights and civil liberties, and to restore transparency ... , The demonstration coincides with a press conference taking place Friday morning calling ...
(Date:3/28/2017)... , ... March 29, 2017 , ... Dr. Isabella Wentz, ... launching a 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey ... which emphasizes the fact that medication IS NOT the only solution to deal with ...
(Date:3/28/2017)... ... 2017 , ... Medforce Technologies, Inc., a leading provider of ... joined the National Association for Home Care and Hospice (NAHC), the largest and ... Americans of all ages and the caregiver who provide them with in-home health ...
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017 Varian Medical Systems (NYSE: ... the second quarter of fiscal year 2017 following the close ... release will be followed by a teleconference available to all ... a link to the conference call webcast will be available ... the teleconference call and replay: ...
(Date:3/29/2017)... 2017  NuVasive, Inc. (NASDAQ: NUVA), a leading ... with minimally disruptive, procedurally-integrated solutions, today announced U.S. ... the CoRoent® Small Interbody™ System indicated for intervertebral ... cervical spine. This marks the first U.S. clearance ... up to four contiguous levels. Cervical ...
(Date:3/29/2017)... NetworkNewsWire Editorial Coverage  ... There are a number ... marijuana, but economic arguments also favor its legalization. The benefits ... costs. However, to legalize and regulate marijuana requires an ecosystem ... SING) ( SING Profile ), American Cannabis Company (OTC: AMMJ), ...
Breaking Medicine Technology: